# To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

> **NCT04728971** · PHASE4 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 200 (estimated)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Micafungin Sodium 50 MG Injection
- **DRUG:** Caspofungin Acetate

## Key facts

- **NCT ID:** NCT04728971
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728971, "To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04728971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*